Go Pro
→ BofA: Digital Dollar Coming 2025-2030 (From Decentralized Masters) (Ad)tc pixel Free BIOG Stock Alerts

The Biotech Growth Trust (BIOG) Competitors

The Biotech Growth Trust logo
GBX 1,624 +12.00 (+0.74%)
As of 07/24/2026 12:25 PM Eastern
Compare

BIOG vs. JFJ, IHP, TMPL, FCSS, and GSS

Should you buy The Biotech Growth Trust stock or one of its competitors? MarketBeat compares The Biotech Growth Trust with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with The Biotech Growth Trust include JPMorgan Japanese (JFJ), IntegraFin (IHP), Temple Bar (TMPL), Fidelity China Special (FCSS), and Genesis Emerging Markets Fund (GSS). These companies are all part of the "asset management" industry.

How does The Biotech Growth Trust compare to JPMorgan Japanese?

JPMorgan Japanese (LON:JFJ) and The Biotech Growth Trust (LON:BIOG) are both small-cap financial services companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

18.9% of JPMorgan Japanese shares are owned by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are owned by institutional investors. 0.1% of JPMorgan Japanese shares are owned by insiders. Comparatively, 3.0% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

JPMorgan Japanese has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59975386, indicating that its stock price is 40% less volatile than the broader market.

In the previous week, The Biotech Growth Trust's average media sentiment score of 1.46 beat JPMorgan Japanese's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
JPMorgan Japanese Neutral
The Biotech Growth Trust Positive

JPMorgan Japanese has a net margin of 96.52% compared to The Biotech Growth Trust's net margin of 96.47%. The Biotech Growth Trust's return on equity of 48.26% beat JPMorgan Japanese's return on equity.

Company Net Margins Return on Equity Return on Assets
JPMorgan Japanese96.52% 20.00% 8.06%
The Biotech Growth Trust 96.47%48.26%12.39%

JPMorgan Japanese has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than JPMorgan Japanese, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
JPMorgan Japanese£245.55M4.85£194.81M£149.065.27
The Biotech Growth Trust£133.86M2.33£83.83M£558.002.91

Summary

JPMorgan Japanese beats The Biotech Growth Trust on 7 of the 12 factors compared between the two stocks.

How does The Biotech Growth Trust compare to IntegraFin?

IntegraFin (LON:IHP) and The Biotech Growth Trust (LON:BIOG) are both small-cap financial services companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

The Biotech Growth Trust has a net margin of 96.47% compared to IntegraFin's net margin of 28.60%. The Biotech Growth Trust's return on equity of 48.26% beat IntegraFin's return on equity.

Company Net Margins Return on Equity Return on Assets
IntegraFin28.60% 27.60% 20.29%
The Biotech Growth Trust 96.47%48.26%12.39%

44.8% of IntegraFin shares are owned by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are owned by institutional investors. 14.5% of IntegraFin shares are owned by insiders. Comparatively, 3.0% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

IntegraFin has a beta of 1.274, suggesting that its share price is 27% more volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59975386, suggesting that its share price is 40% less volatile than the broader market.

The Biotech Growth Trust has lower revenue, but higher earnings than IntegraFin. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than IntegraFin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntegraFin£165.40M7.51£52.54M£19.1019.69
The Biotech Growth Trust£133.86M2.33£83.83M£558.002.91

In the previous week, IntegraFin had 8 more articles in the media than The Biotech Growth Trust. MarketBeat recorded 8 mentions for IntegraFin and 0 mentions for The Biotech Growth Trust. The Biotech Growth Trust's average media sentiment score of 1.46 beat IntegraFin's score of 1.11 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
IntegraFin Positive
The Biotech Growth Trust Positive

IntegraFin currently has a consensus target price of GBX 427, indicating a potential upside of 13.56%. Given IntegraFin's stronger consensus rating and higher probable upside, equities analysts clearly believe IntegraFin is more favorable than The Biotech Growth Trust.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IntegraFin
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
The Biotech Growth Trust
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

IntegraFin beats The Biotech Growth Trust on 11 of the 16 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Temple Bar?

Temple Bar (LON:TMPL) and The Biotech Growth Trust (LON:BIOG) are both small-cap financial services companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

The Biotech Growth Trust has a net margin of 96.47% compared to Temple Bar's net margin of 82.15%. The Biotech Growth Trust's return on equity of 48.26% beat Temple Bar's return on equity.

Company Net Margins Return on Equity Return on Assets
Temple Bar82.15% 27.93% 7.08%
The Biotech Growth Trust 96.47%48.26%12.39%

Temple Bar has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Temple Bar, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Temple Bar£281.60M4.38£154.90M£97.004.19
The Biotech Growth Trust£133.86M2.33£83.83M£558.002.91

Temple Bar has a beta of 1.1421093, indicating that its stock price is 14% more volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59975386, indicating that its stock price is 40% less volatile than the broader market.

10.7% of Temple Bar shares are owned by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are owned by institutional investors. 0.4% of Temple Bar shares are owned by insiders. Comparatively, 3.0% of The Biotech Growth Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, The Biotech Growth Trust's average media sentiment score of 1.46 beat Temple Bar's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
Temple Bar Neutral
The Biotech Growth Trust Positive

Summary

Temple Bar and The Biotech Growth Trust tied by winning 6 of the 12 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Fidelity China Special?

Fidelity China Special (LON:FCSS) and The Biotech Growth Trust (LON:BIOG) are both small-cap financial services companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

7.8% of Fidelity China Special shares are held by institutional investors. Comparatively, 10.5% of The Biotech Growth Trust shares are held by institutional investors. 0.1% of Fidelity China Special shares are held by company insiders. Comparatively, 3.0% of The Biotech Growth Trust shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Fidelity China Special has higher revenue and earnings than The Biotech Growth Trust. The Biotech Growth Trust is trading at a lower price-to-earnings ratio than Fidelity China Special, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fidelity China Special£146.54M8.00£997.06M£29.758.64
The Biotech Growth Trust£133.86M2.33£83.83M£558.002.91

The Biotech Growth Trust has a net margin of 96.47% compared to Fidelity China Special's net margin of 81.41%. The Biotech Growth Trust's return on equity of 48.26% beat Fidelity China Special's return on equity.

Company Net Margins Return on Equity Return on Assets
Fidelity China Special81.41% 9.12% N/A
The Biotech Growth Trust 96.47%48.26%12.39%

Fidelity China Special has a beta of 0.88374627, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, The Biotech Growth Trust has a beta of 0.59975386, suggesting that its stock price is 40% less volatile than the broader market.

In the previous week, The Biotech Growth Trust's average media sentiment score of 1.46 beat Fidelity China Special's score of 0.87 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
Fidelity China Special Positive
The Biotech Growth Trust Positive

Summary

The Biotech Growth Trust beats Fidelity China Special on 7 of the 12 factors compared between the two stocks.

How does The Biotech Growth Trust compare to Genesis Emerging Markets Fund?

Genesis Emerging Markets Fund (LON:GSS) and The Biotech Growth Trust (LON:BIOG) are both small-cap asset management industry companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

In the previous week, The Biotech Growth Trust's average media sentiment score of 1.46 beat Genesis Emerging Markets Fund's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the news media.

Company Overall Sentiment
Genesis Emerging Markets Fund Neutral
The Biotech Growth Trust Positive

10.5% of The Biotech Growth Trust shares are held by institutional investors. 3.0% of The Biotech Growth Trust shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

The Biotech Growth Trust has a net margin of 96.47% compared to Genesis Emerging Markets Fund's net margin of 0.00%. The Biotech Growth Trust's return on equity of 48.26% beat Genesis Emerging Markets Fund's return on equity.

Company Net Margins Return on Equity Return on Assets
Genesis Emerging Markets FundN/A N/A N/A
The Biotech Growth Trust 96.47%48.26%12.39%

The Biotech Growth Trust has lower revenue, but higher earnings than Genesis Emerging Markets Fund. Genesis Emerging Markets Fund is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genesis Emerging Markets Fund£250.40M0.00N/A£140.70N/A
The Biotech Growth Trust£133.86M2.33£83.83M£558.002.91

Summary

The Biotech Growth Trust beats Genesis Emerging Markets Fund on 7 of the 9 factors compared between the two stocks.

Get The Biotech Growth Trust News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIOG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIOG vs. The Competition

Export
MetricThe Biotech Growth TrustAsset Management IndustryFinancial SectorLON Exchange
Market Cap£310.31M£2.54B£5.54B£2.64B
Dividend YieldN/A6.05%5.27%6.15%
P/E Ratio2.9161.3429.41368.39
Price / Sales2.331,784.801,138.5384,479.14
Price / Cash87.7460.50114.0027.89
Price / Book1.511.306.687.41
Net Income£83.83M£265.96M£1.13B£5.89B
7 Day Performance1.88%-0.68%-0.46%0.39%
1 Month Performance7.18%-0.58%-0.18%0.27%
1 Year Performance103.67%6.32%13.15%68.12%

The Biotech Growth Trust Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIOG
The Biotech Growth Trust
N/AGBX 1,624
+0.7%		N/A+103.7%£310.31M£133.86M2.91N/A
JFJ
JPMorgan Japanese
N/AGBX 812.63
-1.0%		N/A+20.4%£1.23B£245.55M5.45N/A
IHP
IntegraFin
4.0858 of 5 stars		GBX 373
-0.8%		GBX 423
+13.4%		-0.4%£1.23B£165.40M19.533,520
TMPL
Temple Bar
N/AGBX 398
+0.3%		N/A+18.4%£1.21B£281.60M4.10N/A
FCSS
Fidelity China Special
N/AGBX 255.50
-0.4%		N/A-7.9%£1.16B£146.54M8.59N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BIOG) was last updated on 7/26/2026 by MarketBeat.com Staff.
From Our Partners
The comeback story of the century (ticker inside)
In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...
InvestorPlace | Sponsoredtc pixel
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Universal basic income is not impossible. It exist (kind of)
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The 90%-off options that empty accounts
A call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...
Profits Run | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel